Linking the growth inhibition response from the National Cancer Institute's anticancer screen to gene expression levels and other molecular target data

Bioinformatics

Volumn 19, Issue 17, 2003, Pages 2212-2224

  Wallqvist, Anders ^a   Rabow, Alfred A ^a   Shoemaker, Robert H ^a   Sausville, Edward A ^a   Covell, David G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE; CELL CYCLE PROTEIN; FIBRILLIN; GLYCOPROTEIN P; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; LIGAND; MESSENGER RNA; PACLITAXEL; PROTEIN MDM2; PROTEIN P16; PROTEIN P21; PROTEIN P53; PROTEIN TYROSINE KINASE;

ARTICLE; CALCIUM SIGNALING; CANCER CENTER; CANCER INHIBITION; CELL COMMUNICATION; CHEMOSENSITIVITY; CORRELATION ANALYSIS; CYTOTOXICITY; DATA ANALYSIS; DRUG SCREENING; ENDOCRINE FUNCTION; GENE EXPRESSION; GENE INDUCTION; GENE MUTATION; HUMAN; MITOSIS; MITOSIS INHIBITION; MULTIDRUG RESISTANCE; MUTANT; NUCLEOTIDE SEQUENCE; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WILD TYPE;

EID: 0344896553     PISSN: 13674803     EISSN: 13674811     Source Type: Journal    
DOI: 10.1093/bioinformatics/btg302     Document Type: Article

References (66)

1. Alvarez,M., Paull,K., Monks,A., Hose,C., Lee,J.-S., Weinstein,J., Grever,M., Bates,S. and Fojo,T. (1995) Generation of a drug resistant profile by quantitation of mdr-1/p-glycoprotein in the cell lines of the National Cancer Institute anticancer drug screen. J. Clin. Invest., 95, 2205-2214.
2. Amundson,S.A., Myers,T.G., Scudiero,D., Kitada,S., Reed,J.C. and Fornace,A.J., Jr. (2000) An informatics approach identifying markers of chemosensitivity in human cancer cells. Cancer Res., 60, 6101-6110.
3. Arner,P., Wahrenberg,H., Lonnqvist,F. and Angelin,B. (1993) Adipocyte beta-adrenoceptor sensitivity influences plasma lipid levels. Arteroscler. Thromb., 13, 967-972.
4. Bartel,S., Vetter,D., Schlegel,W.P., Wallukat,G., Krause,E.G. and Karczewski,P. (2000) Phosphorylation of phospholamban at threonine-17 in the absence and presence of beta-adrenergic stimulation in neonatal rat cardiomyocytes. J. Mol. Cell. Cardiol., 32, 2173-2185.
5. Bjornsson,O.G., Sparks,J.D., Sparks,C.E. and Gibbons,G.F. (1994) Regulation of VLDL secretion in primary culture of rat hepatocytes: involvement of cAMP and cAMP-dependent protein kinases. Eur. J. Clin. Invest., 24, 137-148.
6. Boyd,M. and Paull,K.D. (1995) Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Devel. Res., 34, 91-109.
7. Boyd,M.R. (1995) The NCI in vitro anticancer drug discovery screen. In Teicher,B. (ed.), Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials and Approval. Humana Press, Totowa, NJ, pp. 23-41.
8. Butte,A.J., Tamayo,P., Slonim,D., Golub,T.R. and Kohane,I.S. (2000) Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks. Proc. Natl Acad. Sci. USA, 97, 12182-12186.
9. Chen,C.Y., Oliner,J.D., Zhan,Q., Fornace,A.J., Jr, Vogelstein,B. and Kastan,M.B. (1994) Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl Acad. Sci. USA, 91, 2684-2688.
10. Chiuten,D.F., Vosika,G.J., Shaw,M.T., Boiron,M., Gisselbrecht,C., Marty,M., Higgins,C. and Muggia,F.M. (1981) Clinical trials with diglycoaldehyde (NSC-118994): review and reasons for withdrawal from clinical trial. Anticancer Res., 1, 121-124.
11. Crow,E.L., Davis,F.A. and Maxfield,M.W. (1960) Statistics Manual. Dover, New York.
12. Dan,S., Tsunoda,T., Kitahara,O., Yanagawa,R., Zembutsu,H., Katagiri,T., Yamazaki,K., Nakamura,Y. and Yamori,T. (2002) An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res., 62, 1139-1147.
13. Ding,S., Chamberlain,M., McLaren,A., Goh,L.-B., Duncan,I. and Wolf,C.R. (2001) Cross-talk between signaling pathways and the multidrug resistant protein MDR-1. Br. J. Cancer, 85, 1175-1184.
14. Forootan,S.S., Ke,Y., Jones,A.S. and Helliwell,T.R. (2000) Basic fibroblast growth factor and angiogenesis in squamous carcinoma of the tongue. Oral Oncol., 36, 437-443.
15. Galoyan,A.A., Abrahamian,G.E., Chailyan,S.G., Hashim,G.A. and Lajtha,A. (1994) Calcium- and calmodulin-independent modulation of calmodulin-sensitive hypothalamic cyclic nucleotide phosphodiesterase activity by the (11-19) fragment of thymosin beta 4. Neurochem. Res., 19, 451-456.
16. Hirshman,C.A., Zhu,D., Panettieri,R.A. and Emala,C.W. (2001) Actin depolymerization via the β-adrenoreceptor in airway smooth muscle cells: a novel PKA-independent pathway. Am. J. Physiol. Cell. Physiol., 281, C1468-C1476.
17. Ivanov,S., Lioa,S., Ivanova,A., Danilkovitch-Miagkova,A., Tarasova,N., Weirich,G., Merrill,M.J., Proescholdt,A.A., Oldfield,E.H., Lee,J. et al. (2001) Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am. J. Pathol., 158, 905-919.
18. Ivanov,S.V, Kuzmin,I., Wei,M.-H., Pack,S., Geil,L., Johnson,B.E., Stanbridge,E.J. and Lerman,M.I. (1998) Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc. Natl Acad. Sci. USA, 95, 12596-12601.
19. Jones,N., Voskas,D., Master,Z., Sarao,R., Jones,J. and Dumont,D.J. (2001) Rescue of the early vascular defects in Tek/Tie null mice reveals an essential survival function. EMBO Rep., 2, 438-445.
20. Keskin,O., Bahar,I., Jernigan,R.L., Beutler,J.A., Shoemaker,R.H., Sausville,E.A. and Covell,D.G. (2000) Characterization of anticancer agents by their growth inhibitory activity and relationships to mechanism of action and structure. Anticancer Drug Des., 15, 79-98.
21. Kohonen,T. (1995) Self-Organizing Maps. Springer-Verlag, Germany.
22. Krynetski,E.Y. and Evans,W.E. (1999) Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. Pharm. Res., 16, 342-349.
23. Kubo,A., Nakagawa,K., Varma,R.V., Conrad,N.K., Cheng,J.Q., Lee,W.C., Testa,J.R., Johnson,B.E., Kaye,F.J. and Kelley,M.J. (1999) Thep16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin. Cancer Res., 5, 4279-4286.
24. Kwon,J.H., Eves,E.M., Farrell,S., Segovia,J., Tobin,A.J., Wainer,B.H. and Downen,M. (1996) Beta-adrenergic receptor activation promotes process outgrowth in an embryonic rat basal forebrain cell line and in primary neurons. Eur. J. Neurosci., 8, 2042-2055.
25. Lai,K.O., Ip,F.C., Cheung,J., Fu,A.K. and Ip,N.Y. (2001) Expression of Eph receptors in skeletal muscle and their localization at the neuromuscular junction. Mol. Cell. Neurosci., 17, 1034-1047.
26. Lee,J.S., Paull,K., Alvarez,M., Hose,C., Monks,A., Grever,M., Fojo,A.T. and Bates,S.E. (1994) Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol. Pharmacol., 46, 627-638.
27. Liggett,W.H.,Jr. and Sidransky,D. (1998) Role of the p16 tumor suppressor gene in cancer. J. Clin. Oncol., 16, 1197-1206.
28. Lodish,H., Baltimore,D., Berk,A., Zipursky,S.L., Matsudaira,P. and Dranell,J. (1995) Molecular Cell Biology. Scientific American Books, New York.
29. Loeb,J.A., Susanto,E.T. and Fischbach,G.D. (1998) The neuregulin precursor proARIA is processed to ARIA after expression on the cell surface by a protein kinase C-enhanced mechanism. Mol. Cell. Neurosci., 11, 77-91.
30. McKiernan,J.M., Buttyan,R., Bander,N.H., Stifelman,M.D., Katz,A.E., Chen,M.W., Olsson,C.A. and Sawczuk,I.S. (1997) Expression of the tumor-associated gene MN: a potential biomarker for human renal cell carcinoma. Cancer Res., 57, 2362-2365.
31. Miki,K., Shimizu,E., Yano,S., Tani,K. and Sone,S. (2000) Demethylation by 5-aza-2′-deoxycytidine (5-azadC) of p16INK4A gene results in downregulation of vascular endothelial growth factor expression in human lung cancer cell lines. Oncol. Res., 12, 335-342.
32. Moberg,K.H., Bell,D.W., Wahrer,D.C.R., Haber,D.A. and Hariharan,I.K. (2001) Archipelago regulates cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature, 413, 311-316.
33. Musumarra,G., Condorelli,D.F., Costa,A.S. and Fichera,M. (2001a) A multivariate insight in the in vitro antitumor screen database of the National Cancer Institute: classification of compounds, similarities among cell lines and the influence of molecular targets. J. Comp.-Aided Mol. Des., 15, 219-234.
34. Musumarra,G., Condorelli,D.F., Scire,S. and Costa,A.S. (2001b) Shortcuts in genome-scale cancer pharmacology research from multivariate analysis of the National Cancer Institute gene expression database. Biochem. Pharmacol., 62, 547-553.
35. O'Connor,P.M., Jackman,J., Bae,I., Myers,T.G., Mutoh,S.F.M., Scudiero,D.A., Monks,A., Sausville,E.A., Weinstein,J.N., Friend,S., Fornace,A.J.,Jr. and Kohn,K.W. (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res., 57, 4285-4300.
36. Parkkila,S., Rajaniemi,H., Parkkila,A.-K., Kivalä,J., Waheed,A., Pastorekova,S., Pastorek,J. and Sly,W.S. (2000) Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc. Natl Acad. Sci. USA, 97, 2220-2224.
37. Paull,K.D., Shoemaker,R.H., Hodes,L., Monks,A., Scudiero,D.A., Rubenstein,L., Plowman,J. and Boyd,M.R. (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl Cancer Inst., 81, 1088-1092.
38. Rabow,A.A., Shoemaker,R.H., Sausville,E.A. and Covell,D.G. (2002) Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities. J. Med. Chem., 45, 818-840.
39. Ramaswamy,S., Tamayo,P., Rifki,R., Mukherjee,S., Yeang,C.-H., Angelo,M., Ladd,C., Latulippe,M.R.E., Mesirov,J.P., Poggio,T. et al. (2001) Multiclass cancer diagnosis using tumor gene expression signatures. Proc. Natl Acad. Sci. USA, 98, 15149-15154.
40. Reidhaar-Olson,J.F., Rhees,B.K. and Hammer,J. (2001) Genomics approaches to drug discovery. J. Cell. Biochem., S37, 110-119.
41. Ross,D.T., Scherf,U., Eisen,M.B., Perou,C.M., Rees,C., Spellman,P., Iyer,V., Jeffrey,S.S., van de Rijn,M., Waltham,M. et al. (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat. genet., 24, 227-235.
42. Sato,T.N., Tozawa,Y., Deutsch,U., Wolburg-Buchholz,K., Fujiwara,Y., Gendron-Maguire,M., Gridley,T., Wolburg,H., Risau,W. and Qin,Y. (1995) Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature, 376, 70-74.
43. Schellens,J.H., Pronk,L.C. and Verweij,J. (1996) Emerging drug treatments for solid tumours. Drugs, 51, 45-72.
44. Scherf,U., Ross,D.T., Waltham,M., Smith,L.H., Lee,J.K., Tanabe,L., Kohn,K.W., Reinhold,W.C., Myers,T.G., Andrews,D.T. et al. (2000) A gene expression database for the molecular pharmacology of cancer. Nat. genet., 24, 236-244.
45. Sellers,W.R. and Kaelin,W.G.,Jr. (1997) Role of the retinoblastoma protein in the pathogenesis of human cancer. J. Clin. Oncol., 15, 3301-3312.
46. Serrano,M., Hannon,G.J. and Beach,D.A. (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature, 366, 704-707.
47. Shen,G.X, Cai,W. and Angel,A. (1998) Increased secretion of cholesteryl ester transfer protein from hamster adipose tissue: stimulation by β-adrenergic agents. Atherosclerosis, 140, 113-120.
48. Shi,L.M., Fan,Y., Myers,T.G., Waltham,M., Paull,K.D. and Weinstein,J.N. (1998a) Mining the anticancer activity database generated by the U.S. National Cancer Institute's drug discovery program using statistical and artificial intelligence techniques. Math. Model. Sci. Comput., 38, 189-196.
49. Shi,L.M., Myers,T.G., Fan,Y., O'Connor,P.M., Paull,K.D., Friend,S. and Weinstein,J.N. (1998b) Mining the NCI anticancer drug discovery database: genetic function approximation for the QSAR study of anticancer ellipticine analogues. J. Chem. Inf. Comput. Sci., 38, 189-199.
50. Shields,J.M., Rogers-Graham,K. and Der,C.J. (2002) Loss of transgelin in breast and colon tumors and in RIE-1 cells by ras deregulation of gene expression through raf-independent pathways. J. Biol. Chem., 22, 2304-2317.
51. Staunton,J.E., Slonim,D.K., Coller,H.A., Tamayo,P., Angelo,M.J., Park,J., Scherf,U., Lee,J.K., Reinhold,W.O., Weinstein,J.N. et al. (2001) Chemosensitivity prediction by transcriptional profiling. Proc. Natl Acad. Sci. USA, 98, 10787-10792.
52. Strohmaler,H., Spruck,C.H., Kaiser,P., Won,K.-A., Sangfelt,O. and Reed,S.I. (2001) Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature, 413, 316-322.
53. Su,A.I., Welsh,J.B., Sapinoso,L.M., Kern,S.G., Dimitrov,P., Lapp,H., Schultz,P.G., Powell,S.M., Moskaluk,C.A., Frierson,H.F.,Jr. and Hampton,G.M. (2001) Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res., 61, 7388-7393.
54. Synold,T.W., Dussault,I. and Forman,B.M. (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat. Med., 7, 584-590.
55. Taverna,P., Liu,L., Hanson,A.J., Monks,A. and Gerson,S.L. (2000) Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen. Cancer Chemother. Pharmacol., 46, 507-516.
56. Tureci,O., Sahin,U., Vollmar,E., Siemer,S., Gottert,T.E., Seitz,G., Parkkila,A.K., Shah,G.N., Grubb,H., Pfreundschuh,M. and Sly,W.S. (1998) Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. Proc. Natl Acad. Sci. USA, 95, 7608-7613.
57. van Osdol,W.W., Myers,T.G., Paull,K.D., Kohn,K.W. and Weinstein,J.N. (1994) Use of the Kohonen self-organizing map to study the mechanisms of action of chemotherapeutic agents. J. Natl Canc. Inst., 86, 1853-1859.
58. Voelter,W., Kapuzniotu,A., Mihelic,M., Gurvits,B., Abrahamian,G. and Galoyan,A. (1995) The interaction of (1-4)-fragment of thymosin beta 4 with calmodulin-sensitive cAMP phosphodiesterase from hypothalamus. Neurochem. Res., 20, 55-59.
59. Wallqvist,A., Rabow,A.A., Shoemaker,R.H., Sausville,E.A. and Covell,D.G. (2002) Establishing connections between microarray expression data and chemotherapeutic cancer pharmacology. Mol. Cancer Therapeut., 1, 311-320.
60. iα2 axis controls adipogenesis independently of adenylyl cyclase. Int. J. Obes. Relat. Metab. Disord., 20(Suppl. 3), S26-S31.
61. Weinstein,J.N., Myers,T.G., O'Connor,P.M., Friend,S.H., Fornace,A.J.,Jr., Kohn,K.W., Fojo,T., Bates,S.E., Rubinstein,L.R., Anderson,N.L. et al. (1997) An information-intensive approach to the molecular pharmacology of cancer. Science, 275, 343-349.
62. Wykoff,C.C., Beasley,N., Watson,P.H., Campo,L., Chia,S.K., English,R., Pastorek,J., Sly,W.S., Ratcliffe,P. and Harris,A.L. (2001) Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am. J. Pathol., 158, 1011-1019.
63. Yamauchi,J., Hirasawa,A., Miyamoto,Y., Itoh,H. and Tsujimoto,G. (2001) Beta2-adrenergic receptor/cyclic adenosine monophosphate (cAMP) leads to JNK activation through Rho family small GTPases. Biochem. Biophys. Res. Commun., 284, 1199-1203.
64. Zembutsu,H., Ohnishi,Y., Tsunoda,T., Furukawa,Y., Katagiri,J., Ueyama,Y., Tamaoki,N., Nomura,J., Kitahara,O., Yanagawa,R., Hirata,K. and Nakamura,Y. (2002) Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res., 62, 518-527.
65. Zhang,X.P., Ritke,M.K., Yalowich,J.C., Slovak,M.L., Ho,J.P., Collins,K.I., Annable,T., Arceci,R.J., Durr,F.E. and Greenberger,L.M. (1994) P-glycoprotein mediates profound resistance to bisantrene. Oncol. Res., 6, 291-301.
66. Zhao,R., Gish,K., Murphy,M., Yin,Y., Notterman,D., Hoffman,W.H., Tom,E., Mack,D.H. and Levine,A.J, (2000) Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev., 14, 981-993.